Table 2.
Aberrantly expressed NKL homeobox genes in malignant B-cell lines.
| Gene | Cell Line | Disease | Remarks | Reference |
|---|---|---|---|---|
| HHEX | ||||
| HLX | L-540 DOHH-2 OCI-LY19 NU-DHL-1 SEM |
HL DLBCL DLBCL DLBCL BCP-ALL |
elevated STAT3 activity EBV-mediated STAT3 activation |
[79] [35,94] [99] [99] [99] |
| MSX1 | L-1236 GRANTA-519 JEKO-1 REC-1 |
HL MCL MCL MCL |
cofactor H1C, target ZHX2 t(11;14)(q13;q32) activates CCND1 t(11;14)(q13;q32) activates CCND1 t(11;14)(q13;q32) activates CCND1 |
[82] [85] [85] [85] |
| NANOG | ||||
| NKX2-3 | ||||
| NKX3-1 | ||||
| NKX6-3 | DOHH-2 | DLBCL | repressed by HLX | [35,94] |
| TLX2 | ||||
| VENTX | SEM | BCP-ALL | [99] | |
| BARX2 | RPMI-8226 | MM | [99] | |
| DLX1 | ||||
| EMX2 | ||||
| NKX2-1 | SU-DHL-5 | DLBCL | KMT2A, H2B | [86] |
| NKX2-2 | DEV | HL | activated by IL17RB-signalling | [88] |
| NKX3-2 |
This table lists B-cell lines in which particular NKL homeobox genes are overexpressed. Additionally, the corresponding disease and potentially relevant information are given. The abbreviations are explained in Table 1.